

Reference:	FOI.20573.26
Subject:	Prescribing of Dupiluma
Date of Request:	2 June 2026

Requested:

I am requesting information regarding the prescribing of dupilumab (Dupixent - BNF presentation codes in section 03.04.02) commissioned through the NHS Wales Joint Commissioning Committee (JCC, formerly the Welsh Health Specialised Services Committee /WHSSC) and dispensed across the seven Welsh Local Health Boards.

All requested data should be provided as monthly aggregate counts. Please apply standard NHS statistical disclosure control rules and suppress any cell with a count below 5. Where indication-attribution is not routinely held in a single source, please provide what is available from your standard reporting and indicate which fields are not held.

1. New patient initiations by indication, monthly.

For each calendar month from January 2022 to the date of this request (**2.6.26**), please provide the number of patients newly approved for / newly initiated on dupilumab through JCC (or formerly WHSSC) commissioning, broken down by the indication recorded at point of approval.

Categories of interest: -

- Severe asthma (eosinophilic / type-2 high)
- Chronic obstructive pulmonary disease (COPD)
- Atopic dermatitis
- Chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Eosinophilic oesophagitis (EoE)
- Prurigo nodularis
- Other / not recorded

2. Prevalent patient counts by indication, monthly.

For the same period, please provide the total number of patients receiving ongoing dupilumab treatment funded through JCC / WHSSC commissioning at each month-end, broken down by the same indication categories as Q1.

3. Total dispensed volume and spend, monthly.

For the same period, please provide the total monthly dispensed quantity of dupilumab (in number of pre-filled pen / pre-filled syringe units, summed across all strengths) and the total monthly spend (£, ex VAT) **across all NHS Wales Local Health Boards**.

If indication-attribution is not available at dispensing-grain, the un-broken totals are acceptable. If JCC does not hold dispensing-grain data centrally, please indicate where this is held (e.g. NWSSP) and the unbroken totals at the level you do hold.

Response:

Hywel Dda University Health Board (UHB) does not hold information for all Health Boards in NHS Wales and is therefore unable to provide you with all of the information requested. The UHB can only provide the information it holds.

Therefore, you would need to request the additional information from the Freedom of Information Teams in each individual Health Board. Service and contact details for each of the Health Boards in Wales can be found via the following link:

[Local Services - NHS Wales](#)

The UHB has applied an exemption under Section 43 of the Freedom of Information Act 2000 (FoIA) to the spend requested for question 3 as it relates to third parties and disclosure would be prejudicial to their commercial interests. Section 43(2) exempts information, where disclosure would or would be likely to prejudice the commercial interests of any company.

Commercial interests may be prejudiced where disclosure would, or would be likely to:

- Weaken a company's position in a competitive environment by revealing market sensitive information or information of potential usefulness to its competitors
- Damage a company's business reputation or the confidence that customers/users, suppliers or investors may have in it.

This exemption is qualified; therefore, even if information falls within Section 43, public authorities must then apply the public interest test set out in Section 2(2)(b). The information can only be withheld if the public interest in maintaining the exemption outweighs the public interest in disclosure.

In favour of disclosure: There is a public interest in transparency and accountability of the activities being undertaken by the UHB for the procurement of its medicines, to ensure that real value for money is being achieved, and in turn, to demonstrate the effective use of public funds.

Against Disclosure: Disclosure of the information could impede the UHB's ability to trade competitively within the pharmaceutical sector, as providers would not like to carry the risk of their costings being released into the public domain. Action of this kind could directly impact the UHB's ability to treat patients, should medications not be available for procurement.

Decision: Following consideration of the arguments, the UHB determines that the costing information being requested is commercially confidential in nature, as its use could impact the provider's ability to trade within a competitive market and equally could impact the UHB's ability to procure the treatments required to treat its patients.

However, under the Section 45 Freedom of Information Code of Practice, the UHB has provided the remainder of the information requested below.

1 & 2. The UHB does not hold the requested information as the NHS Wales Joint Commissioning Committee (NWJCC) do not commission the medication Dupilumab (Dupixent).

However, the UHB has answered a similar Freedom of Information request which may be of use to you, FOI. 20538.26 - Biologics in Secondary Care, which is available on our disclosure log.

The UHB has therefore applied an exemption under Section 21 of the FoIA as this information is already in the public domain. A link to the UHB's disclosure log webpage is provided below.

[Disclosure Log - Hywel Dda University Health Board \(nhs.wales\)](#)

Please note:- when using the search function please search by title.

3. The UHB provides the quantities of Dupilumab (Dupixent) dispensed, by month and pack size, during the period 1 January 2022 to 31 May 2026, at Attachment 1.